Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: May, 2014 | Pages:
55 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)
Anacor Pharmaceuticals, Inc. - Product Pipeline Review - 2014 Summary Global Markets Direct's, 'Anacor Pharmaceuticals, Inc. - Product Pipeline Review - 2014', provides an overview of the Anacor Pharmaceuticals, Inc.'s pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of Anacor Pharmaceuticals, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides brief overview of Anacor Pharmaceuticals, Inc. including business description, key information and facts, and its locations and subsidiaries - The report reviews current pipeline of Anacor Pharmaceuticals, Inc.'s human therapeutic division and enlists all their major and minor projects - The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones - Special feature on out-licensed and partnered product portfolio - The report summarizes all the dormant and discontinued pipeline projects - Latest company statement - Latest news and deals relating to the Anacor Pharmaceuticals, Inc.'s pipeline products Reasons to buy - Evaluate Anacor Pharmaceuticals, Inc.'s strategic position with total access to detailed information on its product pipeline - Assess the growth potential of Anacor Pharmaceuticals, Inc. in its therapy areas of focus - Identify new drug targets and therapeutic classes in the Anacor Pharmaceuticals, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps - Develop strategic initiatives by understanding the focus areas of Anacor Pharmaceuticals, Inc. and exploit collaboration and partnership opportunities - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Plan mergers and acquisitions effectively by identifying the most promising pipeline of Anacor Pharmaceuticals, Inc. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Explore the dormant and discontinued projects of Anacor Pharmaceuticals, Inc. and identify potential opportunities in those areas - Avoid Intellectual Property Rights related issues
Table of Contents Table of Contents 2 List of Tables 5 List of Figures 5 Anacor Pharmaceuticals, Inc. Snapshot 6 Anacor Pharmaceuticals, Inc. Overview 6 Key Information 6 Key Facts 6 Anacor Pharmaceuticals, Inc. - Research and Development Overview 7 Key Therapeutic Areas 7 Anacor Pharmaceuticals, Inc. - Pipeline Review 10 Pipeline Products by Stage of Development 10 Pipeline Products - Monotherapy 11 Pipeline Products - Out-Licensed Products 12 Out-Licensed Products/Combination Treatment Modalities 13 Anacor Pharmaceuticals, Inc. - Pipeline Products Glance 14 Anacor Pharmaceuticals, Inc. - Late Stage Pipeline Products 14 Pre-Registration Products/Combination Treatment Modalities 14 Phase III Products/Combination Treatment Modalities 15 Anacor Pharmaceuticals, Inc. - Clinical Stage Pipeline Products 16 Phase II Products/Combination Treatment Modalities 16 Phase I Products/Combination Treatment Modalities 17 Anacor Pharmaceuticals, Inc. - Early Stage Pipeline Products 18 Preclinical Products/Combination Treatment Modalities 18 Discovery Products/Combination Treatment Modalities 19 Anacor Pharmaceuticals, Inc. - Drug Profiles 20 tavaborole 20 Product Description 20 Mechanism of Action 20 R&D Progress 20 AN-2728 22 Product Description 22 Mechanism of Action 22 R&D Progress 22 AN-2898 24 Product Description 24 Mechanism of Action 24 R&D Progress 24 AN-3365 25 Product Description 25 Mechanism of Action 25 R&D Progress 25 AN-2718 27 Product Description 27 Mechanism of Action 27 R&D Progress 27 AN-3485 28 Product Description 28 Mechanism of Action 28 R&D Progress 28 AN-3520 29 Product Description 29 Mechanism of Action 29 R&D Progress 29 AN-3661 30 Product Description 30 Mechanism of Action 30 R&D Progress 30 AN-4161 31 Product Description 31 Mechanism of Action 31 R&D Progress 31 SCYX-6759 32 Product Description 32 Mechanism of Action 32 R&D Progress 32 Boran Based PDE4 Inhibitors 33 Product Description 33 Mechanism of Action 33 R&D Progress 33 Drug Candidates for Nematodal Diseases and TB 34 Product Description 34 Mechanism of Action 34 R&D Progress 34 HCV NS3/4A Serine Protease Inhibitors 35 Product Description 35 Mechanism of Action 35 R&D Progress 35 Oxabarole Backup Compound 36 Product Description 36 Mechanism of Action 36 R&D Progress 36 Anacor Pharmaceuticals, Inc. - Pipeline Analysis 37 Anacor Pharmaceuticals, Inc. - Pipeline Products by Target 37 Anacor Pharmaceuticals, Inc. - Pipeline Products by Route of Administration 39 Anacor Pharmaceuticals, Inc. - Pipeline Products by Molecule Type 40 Anacor Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action 41 Anacor Pharmaceuticals, Inc. - Recent Pipeline Updates 43 Anacor Pharmaceuticals, Inc. - Dormant Projects 51 Anacor Pharmaceuticals, Inc. - Discontinued Pipeline Products 52 Discontinued Pipeline Product Profiles 52 AN-3365 52 Anacor Pharmaceuticals, Inc. - Locations And Subsidiaries 53 Head Office 53 Appendix 54 Methodology 54 Coverage 54 Secondary Research 54 Primary Research 54 Expert Panel Validation 54 Contact Us 55 Disclaimer 55
List of Tables Anacor Pharmaceuticals, Inc., Key Information 6 Anacor Pharmaceuticals, Inc., Key Facts 6 Anacor Pharmaceuticals, Inc. - Pipeline by Indication, 2014 9 Anacor Pharmaceuticals, Inc. - Pipeline by Stage of Development, 2014 10 Anacor Pharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2014 11 Anacor Pharmaceuticals, Inc. - Out-Licensed Products in Pipeline, 2014 12 Anacor Pharmaceuticals, Inc. - Out-Licensed Products/ Combination Treatment Modalities, 2014 13 Anacor Pharmaceuticals, Inc. - Pre-Registration, 2014 14 Anacor Pharmaceuticals, Inc. - Phase III, 2014 15 Anacor Pharmaceuticals, Inc. - Phase II, 2014 16 Anacor Pharmaceuticals, Inc. - Phase I, 2014 17 Anacor Pharmaceuticals, Inc. - Preclinical, 2014 18 Anacor Pharmaceuticals, Inc. - Discovery, 2014 19 Anacor Pharmaceuticals, Inc. - Pipeline by Target, 2014 38 Anacor Pharmaceuticals, Inc. - Pipeline by Route of Administration, 2014 39 Anacor Pharmaceuticals, Inc. - Pipeline by Molecule Type, 2014 40 Anacor Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action, 2014 42 Anacor Pharmaceuticals, Inc. - Recent Pipeline Updates, 2014 43 Anacor Pharmaceuticals, Inc. - Dormant Developmental Projects,2014 51 Anacor Pharmaceuticals, Inc. - Discontinued Pipeline Products, 2014 52
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
